Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 30;18(Supplement_2):ii46-ii54.
doi: 10.1093/ecco-jcc/jjae067.

Considerations on Multimorbidity and Frailty in Inflammatory Bowel Diseases

Isabel Carbery  1 , Christian P Selinger  2 , Oliver Todd  2 , Shaji Sebastian  3
Affiliations
Review

Considerations on Multimorbidity and Frailty in Inflammatory Bowel Diseases

Isabel Carbery et al. J Crohns Colitis. .

Abstract

There are growing numbers of older people with inflammatory bowel diseases [IBD]. These older patients are more likely to have other comorbidities and polypharmacy, which can make recognizing and treating IBD complex. Frailty is a newer concept in the IBD field, and we are beginning to recognize the importance of this as a marker of biological age and its association with risk of adverse IBD-related outcomes. In this review article we aim to provide practical insight into the specific challenges facing older patients and their clinicians at each stage of the patient journey. We also discuss the latest understanding of the impact of frailty for these patients with IBD and highlight areas for future research.

Keywords: Ageing; IBD; frailty.

PubMed Disclaimer

Conflict of interest statement

IC has received speaker honoraria from Celltrion, research grants from Celltrion, and a travel grant from Galapagos. CPS has received unrestricted research grants from Warner Chilcott, Janssen, and AbbVie, has provided consultancy to Warner Chilcott, Dr Falk, AbbVie, Takeda, Fresenius Kabi, Galapagos, Ferring, RedX, Arena, and Janssen, and had speaker arrangements with Warner Chilcott, Dr Falk, AbbVie, MSD, Pfizer, Celltrion, and Takeda. SS has received consulting fees from Celltrion, Lilly, Takeda, AbbVie, Merck, Ferring, Pharmacocosmos, Warner Chilcott, Janssen, Falk Pharma, Biohit, TriGenix, Celgene, and Tillots Pharma, has received payment or honoraria for lectures from AbbVie, Takeda, Celltrion, Pfizer, Biogen, AbbVie, Janssen, Merck, Warner Chilcott, and Falk Pharma Janssen, and holds research grants from Abbvie, Janssen, Takeda, and Olympus. OT reports no conflicts of interest.

References

    1. Coward S, Clement F, Benchimol EI, et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology 2019;156:1345–53.e4. - PubMed
    1. Gisbert JP, Chaparro M.. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Aliment Pharmacol Ther 2014;39:459–77. - PubMed
    1. Sturm A, Maaser C, Mendall M, et al. European Crohn’s and Colitis Organisation topical review on IBD in the elderly. J Crohns Colitis 2017;11:263–73. - PubMed
    1. United Nations. World Population Ageing 2019. New York: Department of Economic and Social Affairs; 2020.
    1. Whitty C. Chief Medical Officer’s Annual Report 2023: Health in an Ageing Society. 2023. https://assets.publishing.service.gov.uk/media/65562ff2d03a8d000d07faa6/....

Grants and funding

LinkOut - more resources